Insulin Resistance

9
Pipeline Programs
7
Companies
6
Clinical Trials
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
6
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
267%
Peptide
133%
+ 5 programs with unclassified modality

On Market (3)

Approved therapies currently available

Novo Nordisk
SAXENDAApproved
liraglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]subcutaneous2014
Novartis
STARLIXApproved
nateglinide
Novartis
oral2000
Novo Nordisk
VICTOZAApproved
liraglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]subcutaneous2010

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
2 programs
1
LiraglutidePhase 4Peptide1 trial
Growth hormoneN/A1 trial
Active Trials
NCT00568568Completed8Est. Feb 2010
NCT02403284Completed97Est. Nov 2023
Bayer
BayerLEVERKUSEN, Germany
1 program
1
NateglinidePhase 41 trial
Active Trials
NCT00259168Completed70Est. Mar 2006
Novartis
NovartisBASEL, Switzerland
1 program
1
NateglinidePhase 4
GS
Gilead SciencesFOSTER CITY, CA
2 programs
2
Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistatPhase 1Small Molecule
Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistatPhase 1Small Molecule1 trial
Active Trials
NCT02203461Completed30Est. Oct 2014
Genentech
GenentechCA - Oceanside
1 program
1
BFKB8488APhase 11 trial
Active Trials
NCT02593331Completed79Est. Mar 2017
Abbott
AbbottABBOTT PARK, IL
1 program
RosiglitazoneN/A1 trial
Active Trials
NCT00186537Completed47Est. Sep 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Novo NordiskLiraglutide
BayerNateglinide
GenentechBFKB8488A
Gilead SciencesTenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat
Novo NordiskGrowth hormone
AbbottRosiglitazone

Clinical Trials (6)

Total enrollment: 331 patients across 6 trials

NCT02403284Novo NordiskLiraglutide

The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans

Start: Mar 2013Est. completion: Nov 202397 patients
Phase 4Completed
NCT00259168BayerNateglinide

Insulin Resistance and Vessel Function After Meals: Does Early Intervention Make a Difference?

Start: Jun 2003Est. completion: Mar 200670 patients
Phase 4Completed
NCT02593331GenentechBFKB8488A

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BFKB8488A in Otherwise Healthy Overweight and Obese Participants With Likely Insulin Resistance

Start: Oct 2015Est. completion: Mar 201779 patients
Phase 1Completed
NCT02203461Gilead SciencesTenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat

Changes in Insulin Resistance in Healthy Volunteers on STRIBILD® Medication

Start: Jul 2014Est. completion: Oct 201430 patients
Phase 1Completed
NCT00568568Novo NordiskGrowth hormone

Metabolic Studies- Interactions Between GH and Insulin in GHDA

Start: Dec 2007Est. completion: Feb 20108 patients
N/ACompleted
NCT00186537AbbottRosiglitazone

Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.

Start: Sep 2003Est. completion: Sep 200847 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 companies competing in this space